Entry inhibitors: New advances in HCV treatment

Hepatitis C virus (HCV) infection affects approximately 3% of the world's population and causes chronic liver diseases, including liver fibrosis, cirrhosis, and hepatocellular carcinoma. Although current antiviral therapy comprising direct-acting antivirals (DAAs) can achieve a quite satisfying...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Xi-Jing, Zhu, Yong-Zhe, Zhao, Ping, Qi, Zhong-Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735057/
https://www.ncbi.nlm.nih.gov/pubmed/26733381
http://dx.doi.org/10.1038/emi.2016.3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735057/
https://www.ncbi.nlm.nih.gov/pubmed/26733381
http://dx.doi.org/10.1038/emi.2016.3

Ejemplares similares